PAR

3.77%

25.5¢ paradigm biopharmaceuticals limited..

Interview with an FDA Process Expert - Pre Questions, page-3

First 3 Last

Share
Profile

Follow
TanamiRod

564 Posts.

234

13/05/21

23:53

Post #: 53165108
Share

Originally posted by Mozzarc: ↑

Apologies for blank post, editor went a bit crazy:

Back in September 2020 we conducted an interview with an FDA Process expert, someone that has been involved with the submission of numerous applications from a broad range of indications

.

Here are the two parts for this interview conducted last year if you haven'tread them:

PART 1

PART 2

I will be sitting down with Mr X. for a follow up mini interview early next week and wanted to ask you guys if you had any questions you would like to add that are related to the FDA application process in general. Note: This guy, we will call him Mr X, has very little specific knowledge of PAR and certainly little to no knowledge of our application and our drug specifically.

Below are some typical questions that I will be asking that have been rounded up from others so far.

Paradigm submitted an IND application to FDA on 26th March 2021 for its drug(PPS) to treat Osteoarthritis. Paradigm received few questions from FDA during the 30 day review period. On 23rd April 2021 the FDA advised Paradigm that it would be putting further questions to the company within the next 30 days.Based on discussions with the FDA Paradigm believes the questions relate to newly submitted non-clinical data which formed part of the IND application.

Questions are:

1. Have you seen or heard of evidence yourself of drug applications being unusually delayed at the FDA at present due to Covid workloads?

2. We are trying to get a sense for how long the IND application might remain on hold and when the IND might open. We believe that once the FDA provide questions to the company and the company responds to such questions the 30 calendar day window restarts. Does the FDA typically try to bundle all questions to the sponsor in one round or can there be multiple rounds of questions?

3. There is some evidence that the drug to be trialled often causes a temporary benign rash at the injection site.
There has been some external suggestion that this could potentially compromise the double blinding aspect of the Phase 3 trial given that it will be known to some people (both administering and participants) as to whether they are receiving the placebo or actual drug. Surely this sort of minor AE occurs regularly in drug trials. Based on your experience what is the FDA's likely view? Would the trial design need to be tweaked to ensure blinding is not compromised?

If you guys can think of any pertinent questions, post below in this thread by Sunday 8pm 16th May. There is no guarantee your (or the above) questions will be asked/answered, subject to usual time constraints etc.

DYOR

Expand

Maybe add that it was a 30,000 page submission. That may help put some context around the delay for Mr X (maybe 30k pages is small in the scheme of things, I honestly don't know).

PAR Price at posting: $2.06 Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

MIN

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

IGO

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

RHK

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Nine's staff strike as Paris Olympic coverage begins

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

HRZ

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

ASX Market Open: ASX200 to rise for Friday session | July 26

NVA

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

MND

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

There are more pages in this discussion • 12 more messages in this thread...

First 3 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 25.5¢		Change -0.010(3.77%)		Mkt cap ! $89.19M

Open	High	Low	Value	Volume
27.0¢	27.0¢	25.5¢	$162.7K	620.9K

Buyers (Bids)

No.	Vol.	Price($)
2	25008	25.5¢

Sellers (Offers)

Price($)	Vol.	No.
26.0¢	34768	1

View Market Depth

No.	Vol.	Price($)
2	25008	0.255
8	215150	0.250
6	109763	0.245
7	91034	0.240
2	54200	0.235

Price($)	Vol.	No.
0.260	34768	1
0.270	500	1
0.275	6347	2
0.290	14580	3
0.295	10000	2

Last trade - 16.10pm 26/07/2024 (20 minute delay)

PAR (ASX) Chart

Interview with an FDA Process Expert - Pre Questions, page-3

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Nine's staff strike as Paris Olympic coverage begins

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

ASX Market Open: ASX200 to rise for Friday session | July 26

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Interview with an FDA Process Expert - Pre Questions, page-3

Top Stories

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Nine's staff strike as Paris Olympic coverage begins

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

ASX Market Open: ASX200 to rise for Friday session | July 26

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News